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Introduction
The development of new drugs can be expensive: on average, 
it costs over $2 billion to take a medication from inception to 
clinical practice. Drug discovery is particularly difficult in 
neuropsychiatric diseases as targets are often poorly defined, 
inaccessible, and not easily assayed. Furthermore, many 
neurological diseases progress slowly over many years, often 
requiring clinical trials examining efficacy to be large and 
have complex end points. However, one way of expediting 
drug development is to repurpose drugs from their original 
use to a new indication. Multiple examples exist in clinical 
medicine: sildenafil was an ineffective angina drug repur-
posed for erectile dysfunction; minoxidil was a hypertension 
drug repurposed for hair loss. These unexpected therapeutic 
discoveries were made serendipitously, and often as side-
effects in clinical trials. Unbiased, high-throughput screens 
are now being used systematically to test libraries of clini-
cally approved drugs in areas of medicine away from their 
usual indications. These screens can generate novel thera-
peutic avenues, shed light on molecular pathology, and lead 
directly to clinical trials.
This month’s journal club explores three papers relat-
ing to drug repurposing in Neurology. The first two papers 
use unbiased cell-based screens of drug/compound librar-
ies to search for potential therapeutic activities relating to 
either Parkinson’s disease or Zika virus infection of neurons, 
respectively. The third paper reports a clinical trial of clem-
astine, commonly used as an antihistamine, in the remyelina-
tion of optic nerves in multiple sclerosis.
β2‑Adrenoreceptor is a regulator 
of the α‑synuclein gene driving risk 
of Parkinson’s disease
Intraneuronal aggregates of phosphorylated α-synuclein 
(Lewy bodies) are found in the brains of patients with Par-
kinson’s disease (PD). Disease severity correlates with Lewy 
body formation, although there is debate about whether 
these aggregates are directly toxic to neurons. Overexpres-
sion of wild-type α-synuclein, either as a result of SNCA 
gene duplication/triplication in familial PD or from gene 
regulatory variants in sporadic disease, can drive PD. Fur-
thermore, decreased α-synuclein production correlates with 
clinical improvement.
This paper reported a high-throughput screening assay 
for compounds that could reduce SNCA gene expression in 
human neuroblastoma cell lines. Cells were grown in multi-
well plates, treated with one of 1126 drugs previously tested 
for safety in humans, and then harvested for gene expres-
sion analysis. Optimisation and replication of the screen 
ultimately identified four drugs that significantly reduced 
SNCA mRNA and protein levels in a dose-dependent man-
ner: three β2-adrenoceptor (β2AR) agonists, including the 
common asthma medication salbutamol, and riluzole, a drug 
licensed in amyotrophic lateral sclerosis. Conversely, β2AR 
inhibition by propranolol, a non-specific β-blocker, led to 
increased SNCA mRNA and protein levels. Extending the 
observations to animal models, intraperitoneal administra-
tion of β2AR agonist clenbuterol to wild-type mice signifi-
cantly reduced SNCA expression in the substantia nigra. 
Similar clenbuterol administration to a mouse model of PD 
prevented nigral neuronal loss.
Finally, the study took advantage of the Norwegian Pre-
scription Database (NorPD) which contains all informa-
tion about individual prescriptions in Norway since 2004. 
Interestingly, if an individual had ever used salbutamol 
(n = 619,863), they had a significantly lower incidence of 
PD (rate ratio = 0.66, 95% confidence interval 0.58–0.76), 
and, conversely, if they had ever used propranolol for at least 
1 year (n = 14,794), they had a significantly increased risk of 
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PD (rate ratio = 2.20, 95% confidence interval 1.62–3.00). 
Adjustments were made for age, sex, and level of education, 
as well as attempts to control for other potential confounders 
such as smoking and essential tremor.
Comment. This study used a well-designed unbiased 
screen to discover compounds that can regulate α-synuclein 
gene expression. Unexpectedly, these included β2AR ago-
nists widely used as asthma medications. The correlation of 
β2AR agonist use and reduced incidence of PD in the large 
Norwegian population fitted in well with the cellular and 
animal work presented, although whether SNCA expression 
is the critical driver of pathology in sporadic PD is unknown. 
Further work is needed to elucidate molecular mechanisms, 
but this should not prevent clinical trials of β2AR agonists 
in PD being fast-tracked.
Mittal S et al (2017) Science 357: 891–898.
Identification of small‑molecule inhibitors 
of Zika virus infection and induced neural 
cell death via a drug repurposing screen
Zika virus (ZIKV) is a mosquito-borne pathogen most 
commonly associated with a mild illness of fever, rash, 
headache, and myalgia. However, recent outbreaks in the 
Pacific islands and Brazil have been associated with seri-
ous neurological sequelae, such as microcephaly in newborn 
infants and Guillain–Barré syndrome in adults. Although 
the molecular pathology of ZIKV infection is incompletely 
understood, recent work has shown that ZIKV can infect 
human neural progenitor cells (hNPCs), inducing caspase-3 
and subsequent cell death. Such neuronal loss, also observed 
following ZIKV infection of brain organoids in vitro, is 
compatible with the observed link between ZIKV and 
microcephaly.
This study screened over 6000 pharmacologically active 
compounds for the inhibition of ZIKV-induced caspase-3 
activation in human glioblastoma cells. A second, inde-
pendent, screen was carried out with the same compounds 
in hNPCs. A total of 116 compounds inhibited caspase-3 
activation in both screens, and these were taken forward to 
cytotoxicity testing. After elimination of cytotoxic drugs, 
two broad classes of active compounds were identified: those 
that directly prevented cell death, and those that inhibited 
ZIKV replication and indirectly prevented cell death. In the 
first group, emricasan, a pan-caspase inhibitor in phase 2 
clinical trials for hepatitis C-related hepatic injury, was an 
effective inhibitor of cell death following ZIKV infection. 
However, it did not inhibit ZIKV replication. In the sec-
ond group, two compounds strongly inhibited ZIKV rep-
lication in cells in a dose-dependent manner. These drugs 
were niclosamide, used for treating worm infections, and an 
investigational cyclin-dependent kinase inhibitor (CDKi). 
Combining emricasan and a CDKi in treatment of ZIKV-
infected hNPCs or astrocytes led to additive inhibition of 
caspase-3 activity as well as improved cell viability.
Comment. The high-throughput screens used in this study 
led to the rapid identification of potential therapeutics for 
ZIKV infection. Pan-caspase inhibitors were, unsurpris-
ingly, found to be protective against caspase-3 activation 
in ZIKV-infected cells. Given the importance of apopto-
sis in normal physiology, these drugs may not have utility 
in ZIKV treatment. In contrast, the discovery of antiviral 
activity associated with niclosamide, an approved drug for 
worm treatment, suggests that repurposing this medication 
for Zika, and potentially other, viral infections could be a 
fruitful therapeutic avenue. Niclosamide can be used in 
pregnancy and so has the potential to be protective against 
microcephaly.
Xu M et al (2016) Nat Med 22: 1101–1107.
Clemastine fumarate as a remyelinating 
therapy for multiple sclerosis (ReBUILD): 
a randomised, controlled, double‑blind, 
crossover trial
Multiple sclerosis (MS) is characterised by inflammation 
and demyelination of neurons in the central nervous sys-
tem (CNS). Current disease-modifying therapies can reduce 
relapse rates, and may delay neuronal loss, but there is no 
evidence that they lead to remyelination of damaged CNS 
neurons. Previous functional drug screens identified clem-
astine, a sedating antihistamine available over-the-counter, 
as having remyelinating potential through its off-target anti-
muscarinic effects. Clemastine can cross the blood–brain 
barrier and is able to drive neuronal remyelination in cell 
and animal models of MS.
This paper reported a phase 2 crossover trial of clemas-
tine and placebo in patients with relapsing–remitting MS 
and chronic demyelinating optic neuropathy on stable immu-
nomodulatory treatment (ReBUILD). Fifty patients were 
randomised 1:1 to either 3 months of clemastine followed 
by 2 months of placebo, or 3 months of placebo followed by 
2 months of clemastine. The two groups were age- and dis-
ability-matched, but there were some differences in sex ratio 
and time since optic neuritis. Forty-six of the fifty patients 
were established on a variety of immunomodulatory thera-
pies, although the drugs taken by the two groups were not 
reported. The primary outcome of the trial was shortening 
of P100 latency delay on visual-evoked potentials (VEPs), 
an indirect readout of optic nerve remyelination. Patients in 
both groups showed improved (shortened) P100 latencies on 
VEPs when taking clemastine, and this effect was sustained 
through the placebo period when clemastine was taken first. 
The improvements were small but statistically significant 
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(mean improvement of 1.7 ms/eye, 95% confidence interval 
0.5–2.9 ms, p = 0.0048, baseline P100 latency > 118 ms). 
A small, correlated improvement in a visual acuity task did 
not reach statistical significance. MRI scans were unchanged 
throughout the study. None of the patients had a clinical 
relapse in the trial, and measures of cognition and dis-
ability were stable. There were no serious adverse events, 
although clemastine was associated with significant fatigue 
as expected for a sedative drug (p = 0.017).
Comment. This small study showed that clemastine may 
lead to small improvements in P100 latencies on VEPs, and 
that these improvements may be sustained after stopping the 
drug. Any small functional improvements in visual acuity 
were not significant, and results were confounded by fatigue 
induced by clemastine. No direct evidence for CNS remy-
elination was presented. The trial had only 50 participants, 
imperfectly matched at baseline between the two study 
groups, and, therefore, lacked the power to detect small 
effect sizes. Furthermore, the trial lasted just 150 days, not 
long enough to measure any long-lasting effects. Therefore, 
although the observations reported are intriguing, further tri-
als with more participants and better controls are warranted.
Green AJ et al (2017) Lancet 390: 2481–2489.
Conclusion
Systematic, strategic drug repurposing is dependent on hav-
ing robust, validated screening assays that bear relevance 
to the disease being targeted. These assays will usually be 
cell-based to allow upscaling and increased throughput, 
and care must be taken to measure meaningful outputs, par-
ticularly in neuropsychiatric diseases. Besides identifying 
potential therapeutics, these screens can also highlight new 
areas of molecular pathology for investigation, as shown in 
the PD and ZIKV studies. A greater understanding of cell 
pathology should enhance screening assays and iteratively 
accelerate drug development. Ultimately, however, large and 
expensive phase 3 clinical trials are still required to dem-
onstrate drug efficacy against a specific disease in humans. 
The repurposing of drugs that are off-patent is unlikely to be 
lucrative for pharmaceutical companies, although adapting 
and developing these compounds may well be more fruitful 
than de novo drug design.
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